Skip to main content
TipRanks
Go Ultimate75% OFF

Omeros (0KBU) Share Price & Analysis

1 Followers

0KBU Stock Chart & Stats

$13.83-$3.33(-19.41%)
At close: 4:30 PM GMT
$15$17.5$20Aug 24Sep 8Sep 21Oct 5Oct 19Nov 2Nov 16
Day’s Range
$12.77 - $15.53
52-Week Range
$6.86 - $21.48
Previous Close
$17.16
Volume
N/A
Average Volume (3M)
2,432
Market Cap
$1.04B
Enterprise Value
$1.59B
Total Cash (Recent Filing)
$131.95M
Total Debt (Recent Filing)
$83.77M
Price to Earnings (P/E)
8.8
Beta
-0.02
Next Earnings
Apr 05, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

YARTEMLEA Commercial Growth

Rapid growth in YARTEMLEA sales across consecutive quarters indicates that the approved product is gaining commercial traction. Continued revenue momentum can improve operating leverage, support investment in the pipeline, and provide a more durable foundation than collaboration income alone.

Broadening Market Adoption

Expansion across transplant-center accounts and purchasing committees strengthens the product's commercial position and increases the potential prescriber and institution base. High penetration among leading centers may support durable adoption as clinical familiarity and institutional access continue to build.

Reimbursement Protection

Favorable reimbursement mechanisms improve the product's economic value for eligible hospitals and protect reimbursement levels over the medium term. NTAP, pass-through status, and ASP-based payment can support uptake and preserve commercial incentives while adoption expands.

Bears Say

Negative Equity And Weak Cash Flow

Negative shareholder equity and sustained cash outflows indicate limited financial flexibility despite recent commercial progress. This capital structure can constrain internally funded investment, increase dependence on financing or transactions, and make the business less resilient if operating cash generation weakens.

European Regulatory Setback

The negative European regulatory opinion removes or delays a potential regional commercialization path for narsoplimab and weakens the near-term breadth of the product opportunity. It also demonstrates that regulatory approval risk remains material for the company's development-led pipeline.

Rising Gross-to-net Deductions

Higher gross-to-net deductions reduce the revenue retained from each dollar of reported gross sales, potentially limiting margin conversion as outpatient and 340B utilization grows. If deductions approach the high teens, commercial expansion may translate into less net revenue than headline sales suggest.

Omeros News

0KBU FAQ

What was Omeros’s price range in the past 12 months?
Omeros lowest share price was $6.86 and its highest was $21.48 in the past 12 months.
What is Omeros’s market cap?
Omeros’s market cap is $1.04B.
When is Omeros’s upcoming earnings report date?
Omeros’s next earnings report is estimated for Apr 05, 2027 (not yet confirmed), which is in 137 days.
How were Omeros’s earnings last quarter?
Omeros released its earnings results on Nov 16, 2026. The company reported -$0.79 earnings per share for the quarter, missing the consensus estimate of $0.02 by -$0.81.
Is Omeros overvalued?
According to Wall Street analysts Omeros’s price is currently Undervalued.
Does Omeros pay dividends?
Omeros does not currently pay dividends.
What is Omeros’s EPS estimate?
Omeros’s EPS estimate is 0.16.
How many shares outstanding does Omeros have?
Omeros has 74,463,570 shares outstanding.
What happened to Omeros’s price movement after its last earnings report?
Omeros reported an EPS of -$0.79 in its last earnings report, missing expectations of $0.02. Following the earnings report the stock price went down -19.406%.
Which hedge fund is a major shareholder of Omeros?
Hedge funds hold Omeros shares: the largest hedge-fund position in Omeros is 638,843,941 shares, and hedge funds decreased their holdings by 23.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology